Connection
Joel Marrs to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Joel Marrs has written about Diabetes Mellitus, Type 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.907 |
|
|
|
-
Fosmire Rundgren EW, Anderson SL, Marrs JC. Response to comment "Evaluation of aspirin use for primary prevention in diabetic patients". Ann Pharmacother. 2015 Feb; 49(2):262-3.
Score: 0.192
-
Fosmire Rundgren EW, Anderson SL, Marrs JC. Evaluation of aspirin use in patients with diabetes receiving care in community health. Ann Pharmacother. 2015 Feb; 49(2):170-7.
Score: 0.187
-
Marrs JC. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. Drugs Aging. 2012 May 01; 29(5):e1-e12.
Score: 0.158
-
Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother. 2012 Apr; 46(4):590-8.
Score: 0.157
-
Marrs JC. Colesevelam for the management of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2009 Feb; 5(2):187-94.
Score: 0.126
-
Luoma KA, Leavitt IM, Marrs JC, Nederveld AL, Regensteiner JG, Dunn AL, Glasgow RE, Huebschmann AG. How can clinical practices pragmatically increase physical activity for patients with type 2 diabetes? A systematic review. Transl Behav Med. 2017 12; 7(4):751-772.
Score: 0.058
-
Marrs JC, Saseen JJ. Which patients are candidates for dipeptidyl peptidase IV inhibitors? Am J Health Syst Pharm. 2007 Jun; 64(12):1261.
Score: 0.028